Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation

NCT02861417 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02861417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02861417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 5, 2016
Completion date
August 31, 2028
Enrollment
204 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphoid cell neoplasm, high risk acute myeloid leukemia, high risk myelodysplastic syndrome, lymphoproliferative disorder, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, recurrent acute lymphoblastic leukemia, recurrent acute myeloid leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent high risk myelodysplastic syndrome, recurrent hodgkin lymphoma, recurrent myelodysplastic syndrome, recurrent non-hodgkin lymphoma, recurrent plasma cell myeloma